

# Characteristics and long-term outcomes of adolescents living with perinatally acquired HIV in the IeDEA-Southern Africa Collaboration: 2004 - 2017

Priscilla Tsondai, Kate Braithewaite, Geoffrey Fatti, Carolyn Bolton, Cleophas Chimbetete, Helena Rabie, Sam Phiri, Shobna Sawry, Brian Eley, Michael A. Hobbins, Andrew Boulle, Katayoun Taghavi, Annette H. Sohn, Mary-Ann Davies

# Disclosures

Authors have no conflicts to declare


# Background

- ~ 1.8m adolescents (10-19 years) are living with HIV across the globe
- ~ 40% live in Southern Africa




# Background

- ~ 1.8m adolescents (10-19 years) are living with HIV across the globe.
- ~ 40% live in Southern Africa



# Background

- ~ 1.8m adolescents (10-19 years) are living with HIV across the globe.
- ~ 40% live in Southern Africa



- ALPH have shown great resilience
  - exposed to HIV very early in life
  - exposed to sub-optimal ART regimens
  - limited pediatric ARV formulations
  - social circumstances

# Objective

- Describe the characteristics and long-term outcomes (mortality, transfers, lost to follow-up (LTFU), viral suppression, and anthropometric measures [weight, height and BMI]) of ALPH in care within leDEA-SA
- Determine predictors of mortality following their 13<sup>th</sup> birthday

# Objective

- Describe the characteristics and long-term outcomes (mortality, transfers, loss to follow-up (LTFU), viral suppression, and anthropometric measures [weight, height and BMI]) of ALPH in care within leDEA-SA
- Determine predictors of mortality following their 13<sup>th</sup> birthday

# Eligibility

- Patients in care within the leDEA-SA sites (2004-2017)
- Likely perinatally infected (assumed if entered care aged  $\leq 13$  years with no documented non-perinatal HIV acquisition)
- Had  $\geq 1$  visit during adolescence (between 10–19 years of age)

# Methods

- Analysed routinely collected data from leDEA-SA sites
- ALPH followed-up from the date of first visit to date of transfer, death, LTFU, or 22<sup>nd</sup> birthday
- LTFU - no contact in the 12 months prior to database closure
- Compared characteristics at enrolment into HIV care, at ART start, and at various ages during adolescence by age of enrolment (<10 vs. 10-13 years)
- Used the Cox Proportional Hazards regression to determine predictors of mortality after the 13<sup>th</sup> birthday




# Sample

25,126 ALPH included  
from 15 sites across 6 countries

---

- South Africa – 44%
- Zambia – 32%
- Malawi – 14%
- Zimbabwe – 8%
- Lesotho & Mozambique – 2%



# Characteristics at enrolment into HIV care

Characteristic at enrolment	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Number	16 229 (65)	8897 (35)	25 126 (100)
Female, n (%)	8159 (50)	4782 (54)	12,941 (51)
Age at enrolment (years), median (IQR)	6.7 (4.4 – 8.4)	11.4 (10.6 – 12.1)	8.6 (5.8 – 10.8)
Year of enrolment, median (IQR)	2008 (2006 – 2010)	2010 (2008 – 2013)	2009 (2006 – 2011)
Severely immunosuppressed, n (%)	5778 (52)	2954 (51)	8732 (51)
CD4 percentage*, median (IQR)	16 (11 – 23)	– –	16 (11 – 23)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	351 (175 – 606)	283 (123 – 488)	321 (148 – 553)
Weight-for-age z-score (WAZ,) median (IQR)	-1.72 (-2.68 – - 0.82)	– –	-1.72 (-2.68 – - 0.82)
Height-for-age z-score (HAZ), median (IQR)	-2.11 (-3.05 – -1.19)	-2.20 (-3.05 – -1.30)	-2.15 (-3.05 – -1.23)
BMI-for-age z-score (BAZ), median (IQR)	-0.41 (-1.34 – 0.44)	-1.07 (-2.01 – -0.27)	-0.67 (-1.62 – 0.21)

\*CD4 % is among those who enrolled aged <5 years.

Absolute CD4 cell count is among those who enrolled aged  $\geq$ 5 years

# Characteristics at enrolment into HIV care

Characteristic at enrolment	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Number	16 229 (65)	8897 (35)	25 126 (100)
Female, n (%)	8159 (50)	4782 (54)	12,941 (51)
Age at enrolment (years), median (IQR)	6.7 (4.4 – 8.4)	11.4 (10.6 – 12.1)	8.6 (5.8 – 10.8)
Year of enrolment, median (IQR)	2008 (2006 – 2010)	2010 (2008 – 2013)	2009 (2006 – 2011)
Severely immunosuppressed, n (%)	5778 (52)	2954 (51)	8732 (51)
CD4 percentage*, median (IQR)	16 (11 – 23)	– –	16 (11 – 23)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	351 (175 – 606)	283 (123 – 488)	321 (148 – 553)
Weight-for-age z-score (WAZ,) median (IQR)	-1.72 (-2.68 – - 0.82)	– –	-1.72 (-2.68 – - 0.82)
Height-for-age z-score (HAZ), median (IQR)	-2.11 (-3.05 – -1.19)	-2.20 (-3.05 – -1.30)	-2.15 (-3.05 – -1.23)
BMI-for-age z-score (BAZ), median (IQR)	-0.41 (-1.34 – 0.44)	-1.07 (-2.01 – -0.27)	-0.67 (-1.62 – 0.21)

\*CD4 % is among those who enrolled aged <5 years.

Absolute CD4 cell count is among those who enrolled aged  $\geq$ 5 years

# Characteristics at enrolment into HIV care

Characteristic at enrolment	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Number	16 229 (65)	8897 (35)	25 126 (100)
Female, n (%)	8159 (50)	4782 (54)	12,941 (51)
Age at enrolment (years), median (IQR)	6.7 (4.4 – 8.4)	11.4 (10.6 – 12.1)	8.6 (5.8 – 10.8)
Year of enrolment, median (IQR)	2008 (2006 – 2010)	2010 (2008 – 2013)	2009 (2006 – 2011)
Severely immunosuppressed, n (%)	5778 (52)	2954 (51)	8732 (51)
CD4 percentage*, median (IQR)	16 (11 – 23)	– –	16 (11 – 23)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	351 (175 – 606)	283 (123 – 488)	321 (148 – 553)
Weight-for-age z-score (WAZ,) median (IQR)	-1.72 (-2.68 – - 0.82)	– –	-1.72 (-2.68 – - 0.82)
Height-for-age z-score (HAZ), median (IQR)	-2.11 (-3.05 – -1.19)	-2.20 (-3.05 – -1.30)	-2.15 (-3.05 – -1.23)
BMI-for-age z-score (BAZ), median (IQR)	-0.41 (-1.34 – 0.44)	-1.07 (-2.01 – -0.27)	-0.67 (-1.62 – 0.21)

\*CD4 % is among those who enrolled aged <5 years.

Absolute CD4 cell count is among those who enrolled aged  $\geq$ 5 years

# Characteristics at enrolment into HIV care

Characteristic at enrolment	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Number	16 229 (65)	8897 (35)	25 126 (100)
Female, n (%)	8159 (50)	4782 (54)	12,941 (51)
Age at enrolment (years), median (IQR)	6.7 (4.4 – 8.4)	11.4 (10.6 – 12.1)	8.6 (5.8 – 10.8)
Year of enrolment, median (IQR)	2008 (2006 – 2010)	2010 (2008 – 2013)	2009 (2006 – 2011)
Severely immunosuppressed, n (%)	5778 (52)	2954 (51)	8732 (51)
CD4 percentage*, median (IQR)	16 (11 – 23)	– –	16 (11 – 23)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	351 (175 – 606)	283 (123 – 488)	321 (148 – 553)
Weight-for-age z-score (WAZ,) median (IQR)	-1.72 (-2.68 – - 0.82)	– –	-1.72 (-2.68 – - 0.82)
Height-for-age z-score (HAZ), median (IQR)	-2.11 (-3.05 – -1.19)	-2.20 (-3.05 – -1.30)	-2.15 (-3.05 – -1.23)
BMI-for-age z-score (BAZ), median (IQR)	-0.41 (-1.34 – 0.44)	-1.07 (-2.01 – -0.27)	-0.67 (-1.62 – 0.21)

\*CD4 % is among those who enrolled aged <5 years.

Absolute CD4 cell count is among those who enrolled aged  $\geq$ 5 years

# Characteristics at enrolment into HIV care

Characteristic at enrolment	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Number	16 229 (65)	8897 (35)	25 126 (100)
Female, n (%)	8159 (50)	4782 (54)	12,941 (51)
Age at enrolment (years), median (IQR)	6.7 (4.4 – 8.4)	11.4 (10.6 – 12.1)	8.6 (5.8 – 10.8)
Year of enrolment, median (IQR)	2008 (2006 – 2010)	2010 (2008 – 2013)	2009 (2006 – 2011)
Severely immunosuppressed, n (%)	5778 (52)	2954 (51)	8732 (51)
CD4 percentage*, median (IQR)	16 (11 – 23)	– –	16 (11 – 23)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	351 (175 – 606)	283 (123 – 488)	321 (148 – 553)
Weight-for-age z-score (WAZ,) median (IQR)	-1.72 (-2.68 – - 0.82)	– –	-1.72 (-2.68 – - 0.82)
Height-for-age z-score (HAZ), median (IQR)	-2.11 (-3.05 – -1.19)	-2.20 (-3.05 – -1.30)	-2.15 (-3.05 – -1.23)
BMI-for-age z-score (BAZ), median (IQR)	-0.41 (-1.34 – 0.44)	-1.07 (-2.01 – -0.27)	-0.67 (-1.62 – 0.21)

\*CD4 % is among those who enrolled aged <5 years.

Absolute CD4 cell count is among those who enrolled aged  $\geq$ 5 years

# Characteristics at enrolment into HIV care

Characteristic at enrolment	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Number	16 229 (65)	8897 (35)	25 126 (100)
Female, n (%)	8159 (50)	4782 (54)	12,941 (51)
Age at enrolment (years), median (IQR)	6.7 (4.4 – 8.4)	11.4 (10.6 – 12.1)	8.6 (5.8 – 10.8)
Year of enrolment, median (IQR)	2008 (2006 – 2010)	2010 (2008 – 2013)	2009 (2006 – 2011)
Severely immunosuppressed, n (%)	5778 (52)	2954 (51)	8732 (51)
CD4 percentage*, median (IQR)	16 (11 – 23)	– –	16 (11 – 23)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	351 (175 – 606)	283 (123 – 488)	321 (148 – 553)
Weight-for-age z-score (WAZ,) median (IQR)	-1.72 (-2.68 – - 0.82)	– –	-1.72 (-2.68 – - 0.82)
Height-for-age z-score (HAZ), median (IQR)	-2.11 (-3.05 – -1.19)	-2.20 (-3.05 – -1.30)	-2.15 (-3.05 – -1.23)
BMI-for-age z-score (BAZ), median (IQR)	-0.41 (-1.34 – 0.44)	-1.07 (-2.01 – -0.27)	-0.67 (-1.62 – 0.21)

\*CD4 % is among those who enrolled aged <5 years.

Absolute CD4 cell count is among those who enrolled aged  $\geq$ 5 years

# Characteristics at enrolment into HIV care

Characteristic at enrolment	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Number	16 229 (65)	8897 (35)	25 126 (100)
Female, n (%)	8159 (50)	4782 (54)	12,941 (51)
Age at enrolment (years), median (IQR)	6.7 (4.4 – 8.4)	11.4 (10.6 – 12.1)	8.6 (5.8 – 10.8)
Year of enrolment, median (IQR)	2008 (2006 – 2010)	2010 (2008 – 2013)	2009 (2006 – 2011)
Severely immunosuppressed, n (%)	5778 (52)	2954 (51)	8732 (51)
CD4 percentage*, median (IQR)	16 (11 – 23)	– –	16 (11 – 23)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	351 (175 – 606)	283 (123 – 488)	321 (148 – 553)
Weight-for-age z-score (WAZ,) median (IQR)	-1.72 (-2.68 – - 0.82)	– –	-1.72 (-2.68 – - 0.82)
Height-for-age z-score (HAZ), median (IQR)	-2.11 (-3.05 – -1.19)	-2.20 (-3.05 – -1.30)	-2.15 (-3.05 – -1.23)
BMI-for-age z-score (BAZ), median (IQR)	-0.41 (-1.34 – 0.44)	-1.07 (-2.01 – -0.27)	-0.67 (-1.62 – 0.21)

\*CD4 % is among those who enrolled aged <5 years.

Absolute CD4 cell count is among those who enrolled aged  $\geq$ 5 years



# Characteristics at enrolment into HIV care

Characteristic at enrolment	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Number	16 229 (65)	8897 (35)	25 126 (100)
Female, n (%)	8159 (50)	4782 (54)	12,941 (51)
Age at enrolment (years), median (IQR)	6.7 (4.4 – 8.4)	11.4 (10.6 – 12.1)	8.6 (5.8 – 10.8)
Year of enrolment, median (IQR)	2008 (2006 – 2010)	2010 (2008 – 2013)	2009 (2006 – 2011)
Severely immunosuppressed, n (%)	5778 (52)	2954 (51)	8732 (51)
CD4 percentage*, median (IQR)	16 (11 – 23)	– –	16 (11 – 23)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	351 (175 – 606)	283 (123 – 488)	321 (148 – 553)
Weight-for-age z-score (WAZ,) median (IQR)	-1.72 (-2.68 – - 0.82)	– –	-1.72 (-2.68 – - 0.82)
Height-for-age z-score (HAZ), median (IQR)	-2.11 (-3.05 – -1.19)	-2.20 (-3.05 – -1.30)	-2.15 (-3.05 – -1.23)
BMI-for-age z-score (BAZ), median (IQR)	-0.41 (-1.34 – 0.44)	-1.07 (-2.01 – -0.27)	-0.67 (-1.62 – 0.21)

\*CD4 % is among those who enrolled aged <5 years.

Absolute CD4 cell count is among those who enrolled aged  $\geq$ 5 years

# Characteristics at ART initiation

Characteristic	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Ever initiated ART, n (%)	15 883 (98)	7770 (87)	23 653 (94)
Age at ART start (years), median (IQR)	7.2 (4.8 – 8.9)	11.6 (10.8 – 12.3)	8.9 (6.1 – 10.9)
Year of ART start, median (IQR)	2008 (2006– 2011)	2010 (2008–2013)	2009 (2007–2011)
WHO clinical stage 3/4, n (%)	7119 (64)	3304 (59)	10,423 (63)
Severely immunosuppressed, n (%)	5850 (54)	2791 (56)	8641 (55)
CD4 percentage*, median (IQR)	15.0 (10.0 – 21.1)	–	15.0 (10.0 – 21.1)
CD4 cell count* (cells/μL), median (IQR)	329 (170 – 568)	251 (109 – 423)	297 (142 – 505)
HAZ, median (IQR)	-2.12 (-3.03– -1.22)	-2.24 (-3.06– -1.36)	-2.16 (-3.05– -1.27)
<b>First line regimen</b>			
EFV/NVP	13 512 (91)	7122 (98)	20 634 (94)

\*CD4 % is among those who initiated ART aged <5 years.

Absolute CD4 cell count is among those who initiated ART aged ≥5 years

# Characteristics at ART initiation

Characteristic	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Ever initiated ART, n (%)	15 883 (98)	7770 (87)	23 653 (94)
Age at ART start (years), median (IQR)	7.2 (4.8 – 8.9)	11.6 (10.8 – 12.3)	8.9 (6.1 – 10.9)
Year of ART start, median (IQR)	2008 (2006– 2011)	2010 (2008–2013)	2009 (2007–2011)
WHO clinical stage 3/4, n (%)	7119 (64)	3304 (59)	10,423 (63)
Severely immunosuppressed, n (%)	5850 (54)	2791 (56)	8641 (55)
CD4 percentage*, median (IQR)	15.0 (10.0 – 21.1)	–	15.0 (10.0 – 21.1)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	329 (170 – 568)	251 (109 – 423)	297 (142 – 505)
HAZ, median (IQR)	-2.12 (-3.03– -1.22)	-2.24 (-3.06– -1.36)	-2.16 (-3.05– -1.27)
<b>First line regimen</b>			
EFV/NVP	13 512 (91)	7122 (98)	20 634 (94)

\*CD4 % is among those who initiated ART aged <5 years.

Absolute CD4 cell count is among those who initiated ART aged  $\geq$ 5 years

# Characteristics at ART initiation

Characteristic	Age at enrolment <10 years	Age at enrolment 10-13 years	All
Ever initiated ART, n (%)	15 883 (98)	7770 (87)	23 653 (94)
Age at ART start (years), median (IQR)	7.2 (4.8 – 8.9)	11.6 (10.8 – 12.3)	8.9 (6.1 – 10.9)
Year of ART start, median (IQR)	2008 (2006– 2011)	2010 (2008–2013)	2009 (2007–2011)
WHO clinical stage 3/4, n (%)	7119 (64)	3304 (59)	10,423 (63)
<b>Severely immunosuppressed, n (%)</b>	<b>5850 (54)</b>	<b>2791 (56)</b>	<b>8641 (55)</b>
CD4 percentage*, median (IQR)	15.0 (10.0 – 21.1)	–	15.0 (10.0 – 21.1)
CD4 cell count* (cells/ $\mu$ L), median (IQR)	329 (170 – 568)	251 (109 – 423)	297 (142 – 505)
HAZ, median (IQR)	-2.12 (-3.03– -1.22)	-2.24 (-3.06– -1.36)	-2.16 (-3.05– -1.27)
<b>First line regimen</b>			
EFV/NVP	13 512 (91)	7122 (98)	20 634 (94)

\*CD4 % is among those who initiated ART aged <5 years.

Absolute CD4 cell count is among those who initiated ART aged  $\geq$ 5 years

# Characteristics at entry into adolescence (age 10 years) (N=16 229)

Characteristic	Median	IQR
Duration on ART (years)	3	(1.4 – 5.3)
CD4 cell count (cells/ $\mu$ L)	716	(465 – 1009)


# Characteristics at entry into adolescence (age 10 years) (N=16 229)

Characteristic	Median	IQR
Duration on ART (years)	3	(1.4 – 5.3)
CD4 cell count (cells/ $\mu$ L)	716	(465 – 1009)

# Characteristics at entry into adolescence (age 10 years) (N=16 229)

Characteristic	Median	IQR
Duration on ART (years)	3	(1.4 – 5.3)
CD4 cell count (cells/ $\mu$ L)	716	(465 – 1009)


- 89% on an NNRTI-based regimen
- ~ 55% had weight and height measures
  - 38% stunted (HAZ < -2)
  - 27% underweight (WAZ < -2)



# Characteristics at entry into adolescence (age 10 years) (N=16 229)


Characteristic	Median	IQR
Duration on ART (years)	3	(1.4 – 5.3)
CD4 cell count (cells/ $\mu$ L)	716	(465 – 1009)

- 89% on an NNRTI-based regimen
- ~ 55% had weight and height measures
  - 38% stunted (HAZ <-2)
  - 27% underweight (WAZ <-2)
- Among those in care within sites with routine VL testing (n=7331)
  - 73% had a VL measure
  - 78% had a VL  $\leq$ 400 copies/mL






# Cross-sectional outcomes at database closure




# Cross-sectional outcomes at database closure

## Enrolled aged <10 years



## Enrolled aged 10-13 years




# ALPH age distribution wave




# ALPH age distribution wave

Outcome	At 13 years	At 15 years	At 18 years
Died	1.5%	2%	3%
TFO	7%	12%	15%
LTFU	12%	17%	21%
In care & < 13, 15 or 18 years	22%	35%	49%
Retained	57%	34%	13%


At 13 years



At 15 years



At 18 years







# ALPH age distribution wave

Outcome	At 13 years	At 15 years	At 18 years
Died	1.5%	2%	3%
TFO	7%	12%	15%
LTFU	12%	17%	21%
In care & < 13, 15 or 18 years	22%	35%	49%
Retained	57%	34%	13%


At 13 years




At 15 years



At 18 years




# Median (IQR) CD4 cell count across various ages by age of enrolment





Age (years)	11	12	13	14	15	16	17	18	19
N	7906	7830	7141	5735	4453	3363	2450	1634	991

# Median (IQR) CD4 cell count across various ages by calendar period



Age (years)	11	12	13	14	15	16	17	18	19
N	7906	7830	7141	5735	4453	3363	2450	1634	991

# Median (IQR) HAZ across various ages



Age (years)	11	12	13	14	15	16	17	18	19
N	8171	7999	7343	5705	4509	3485	2582	1773	965



# Predictors of mortality following the 13<sup>th</sup> birthday

Characteristic	Adjusted HR (95% CI)	P-value
Age at enrolment <10 years (vs. 10-13)	0.80 (0.53 – 1.22)	0.30
Female (vs. male)	1.24 (0.90 – 1.72)	0.19
Increasing calendar year of 13 <sup>th</sup> birthday	0.84 (0.78 – 0.90)	<0.01
CD4 cell count (vs. <350 cell/ $\mu$ L)		
350 – 500	0.47 (0.30 – 0.73)	<0.01
>500	0.18 (0.12 – 0.27)	<0.01

\*Also adjusted for site

# Conclusion

- ALPH have suboptimal retention, viral suppression and survival during adolescence but some outcomes improving in recent years
- ALPH enrolling into HIV care after the age of 10 years have poorer outcomes compared to those who enrolled before the age of 10 years
- ALPH identified as late enrollers need close monitoring to optimize their treatment outcomes.
- Strongest predictors of mortality after the age of 13 years were immunological status and calendar year of 13<sup>th</sup> birthday.

# Acknowledgement

Patients & site staff

Mary-Ann Davies & Annette Sohn

University of Cape Town leDEA-SA Data Centre

This project was supported by Grant Number U01AI069924 from NIH (NIAID, NICHD, NCI, NIDA, NIMH) (PI: Egger and Davies). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

